BIPHETAMINE 7.5
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIPHETAMINE 7.5 is an oral extended-release capsule containing amphetamine salts, approved in 1955 by UCB Pharma. The drug's mechanism of action involves sympathomimetic stimulation of the central nervous system. It is indicated for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy in patients requiring sustained CNS stimulation.
LOE Approaching
As LOE approaches, commercial teams face revenue headwinds and team downsizing; expect focus on retention and managed decline strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BIPHETAMINE 7.5 offers exposure to legacy product management and controlled substance compliance expertise, but limited growth trajectory. Career advancement requires contributing to managed decline strategy or transitioning to growth-stage products within the portfolio.
Brand ManagerMarket Access Manager
Worked on BIPHETAMINE 7.5 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.